Astellas Provides Update on ASPIRO Clinical Trial of AT132 i

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced that it has voluntarily paused screening and...

Related Keywords

Tokyo , Japan , North Carolina , United States , South San Francisco , California , San Francisco , Kenji Yasukawa , Nathan Bachtell , Drug Administration , Data Monitoring Committee , Liver Advisory Panel , Astellas Pharma Inc , European Medicines Agency , Astellas Center , Development At Astellas , Audentes Therapeutics Inc , Astellas Pharma , X Linked Myotubular Myopathy , Investigational New Drug , Senior Vice President , Gene Therapy , Astellas Medical Monitor , X Linked Myotubular , Regenerative Medicine , Advanced Therapy , Rare Pediatric Disease , Fast Track , Orphan Drug , Priority Medicines , Audentes Therapeutics , Focus Area Approach ,